Adding Plavix to Aspirin for Preventing Small Strokes May Increase Death Risk
Study stopped early due to
increased bleeding compared to aspirin alone
Feb. 6, 2012 - The anti-blood clot regimen that adds the drug Plavix (clopidogrel) to aspirin treatment is unlikely to
prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking
research presented Friday at the American Stroke Association’s International Stroke Conference 2012.
Because of these preliminary results, researchers ended the anti-clotting part of the Secondary Prevention of Small
Subcortical Strokes Trial (SPS3) in August 2011. The part of the study that examines the effect of high blood pressure treatments will
The SPS3 trial is the first large-scale study of patients with subcortical strokes, which occur when small blood vessels
deep in the middle of the brain are blocked, damaging small areas of brain tissue.
This type of stroke affects about 150,000 Americans each year, and is the most common cause of vascular dementia
according to Oscar Benavente, M.D., lead author of the study and a professor of neurology at Canada’s University of British Columbia in
Vancouver, British Columbia. Co-investigator is Robert G. Hart, M.D.
American Heart Association/American Stroke Association guidelines for preventing recurrent strokes recommend
anti-clotting medications like aspirin, the customary treatment, or other clot preventives like clopidogrel
(Plavix), but not the combination of aspirin plus clopidogrel.
Treatments have not been compared in patients with subcortical strokes specifically.
In the United States, stroke is the No. 4 killer and a leading cause of disability among adults.
Beginning in March 2003, the SPS3 study included 3,020 patients at 81 sites in the United States, Canada, Spain, Mexico
and South America. Stroke patients were randomly assigned within 180 days of symptom onset to receive aspirin and clopidogrel or aspirin plus
placebo daily. Neither researchers nor patients knew who received placebo or the study drug.
Preliminary findings showed that the risk of bleeding nearly doubled among patients on the clopidogrel/aspirin
combination, compared to those on aspirin and placebo. Aspirin plus placebo had a 1.1 percent of bleeding risk per year and aspirin plus
clopidogrel a 2.1 percent bleeding risk per year – largely from major bleeds somewhere other than in the brain.
Similarly, the annual risk of death was greater with the combined therapy. Aspirin plus placebo had a 1.4 percent risk of
death and aspirin plus clopidogrel had a 2.1 percent risk of death.
There was no difference in stroke recurrence in both treatment arms.
“These interim results do not support the use of combination clopidogrel plus aspirin for secondary stroke prevention in
patients with small subcortical strokes,” the researchers said.
The National Institutes of Health, National Institute of Neurological Diseases and Stroke, funded the study.
> Nursing Home Abuse,
> Personal Injury
Our Experienced Lawyers Can Help
"We win because we care, we prepare
and we have no fear," Beth Janicek, board certified personal